ERYtech Pharma and Genzyme Corporation Sign Collaborative Research Agreement in Rare Diseases

18-Oct-2010 - France

ERYtech Pharma is pleased to announce it has signed a collaborative research agreement with Genzyme Corporation to explore the feasibility of developing a novel therapeutic enzyme formulation using ERYtech’s proprietary technology.

Both companies will collaborate over the next 15 months to perform feasibility studies with encapsulating the enzyme and testing the new formulation in preclinical studies. Genzyme has an option to enter into a broader licensing agreement for development and commercialization of this product. Other terms of the deal were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances